Abstract Library

#3029 Adrenocortical Carcinoma Metastasic in Adult on Complete Response with EDP-M and Local Therapy: A Single Case Report

Introduction: Adrenocortical carcinoma (ACC) in adults is a rare tumor (incidence 0.7-2/1000000/year). Median overall survival is 3-4 years and five-year survival is 0-28% in metastatic disease. The only curative therapy is complete surgical resection, plus adjuvant therapy depending on poor prognostic factors (ENSAT stage III, R1 resection or Ki67>10%). Both recurrent oligometastatic disease and patients who respond to systemic treatment (ST), a radical approach with surgery or local therapy (LT) may be treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Morales Herrero R, Herrero Rivera D, Santos Fernández P, Benavent M,

Keywords: ACC, chemotherapy, mitotane, local therapy,

#2256 Assessment of the Serum Levels of the Soluble Vascular Cellular Adhesion Molecule-1 (sVCAM-1) in Patients with Neuroendocrine Neoplasms

Introduction: Tumor growth and the ability to metastasize is a multistage process involving interactions between cancer cells and the vascular endothelium. These interactions have been reported to be mediated by various molecules including sVCAM-1. We have previously shown elevated serum concentration of sVCAM-1 in 82 neuroendocrine neoplasms (NEN) compared to controls. Here, we present results of the extension of the previous study.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Malczewska A

Authors: Rosiek V, Malczewska A, Kos-Kudła B,

Keywords: neuroendocrine neoplasms, adhesion molecule, metastasis,

#2092 Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors

Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are known to develop mesenteric metastasis and fibrosis. Since this can induce intestinal obstruction, edema and ischaemia, prophylactic palliative resection of the primary tumour and mesenteric mass is often recommended in case of advanced disease but the evidence is disputable.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Blazevic A

Authors: Blazevic A, Zandee W, Franssen G, Hofland J, Van Velthuysen M,

Keywords: Small intestinal neuroendocrine tumors, Palliative surgery, Prognosis,

#1448 Distribution of T-Cell Infiltrate in G1, G2 and G3 NENs

Introduction: The identification of T-cell infiltrate and the expression of inhibitory molecules in the tumor microenvironment could lend support to the use of immunotherapy in the treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Milione M

Authors: Milione M, Pellegrinelli A, Centonze G, Dominoni F, Pusceddu S,

Keywords: Ki-67, T-cells, NEN,

#556 Unresectable Mesenteric Midgut NETs: Are They a Unique Prognostic Category?

Introduction: Patients with lymph-node positive midgut NETs (stage IIIB) represent a heterogeneous group. While some have microscopic lymph node involvement on pathological evaluation, others may develop large, desmoplastic, unresectable tumors in the root of the mesentery.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Strosberg J, Weber J, Feldman M, Kvols L,

Keywords: neuroendocrine tumors, carcinoid tumor, midgut, lymph node metastases, stage III,